scholarly journals Carbidopa and Levodopa Extended Release Capsules (Rytary®) in Patients with and without Troublesome and Non-Troublesome Dyskinesia

2020 ◽  
pp. 1-11
Author(s):  
Robert A. Hauser ◽  
Leonid Zeitlin ◽  
Stanley Fisher ◽  
Richard D’Souza
2019 ◽  
Vol 9 (4) ◽  
pp. 205-215 ◽  
Author(s):  
Azalea T Pajo ◽  
Adrian I Espiritu ◽  
Roland Dominic G Jamora

Aim: To determine the effectiveness and safety of extended-release amantadine (ADS-5102) for levodopa-induced dyskinesias (LID) in patients with Parkinson disease (PD) by conducting a meta-analysis of relevant trials. Methods: The electronic databases were searched on or before March 1, 2019 for relevant trials. Only randomized, double-blind, parallel-group, placebo-controlled trials using ADS-5102 for LID in PD were included. Results: The ADS-5102 showed a reduction in the dyskinesia scores (mean difference: -9.56: CI: -10.05 to -9.07; p < 0.00001) and in the on time without troublesome dyskinesia (mean difference 2.50: CI 2.38 to 2.63; p < 0.00001). The adverse events identified in ADS-5102 were visual hallucinations, constipation, dry mouth and fall. Conclusion: ADS-5102 can be used as an adjunct therapy for LID.


2006 ◽  
Vol 175 (4S) ◽  
pp. 409-409 ◽  
Author(s):  
Gary Kay ◽  
Thomas Crook ◽  
Ludmyla Rekeda ◽  
Raul Lima

2008 ◽  
Vol 42 (2) ◽  
pp. 28 ◽  
Author(s):  
ROBERT FINN
Keyword(s):  

2016 ◽  
Vol 22 ◽  
pp. 69
Author(s):  
Hemant Thacker ◽  
Rajeev Chawla ◽  
Navneet Agrawal ◽  
Rohit Kapoor ◽  
Noel Somasundaram ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document